Literature DB >> 15024080

The Brn-2 transcription factor links activated BRAF to melanoma proliferation.

Jane Goodall1, Claudia Wellbrock, Timothy J Dexter, Karen Roberts, Richard Marais, Colin R Goding.   

Abstract

Malignant melanoma, an aggressive and increasingly common cancer, is characterized by a strikingly high rate (70%) of mutations in BRAF, a key component of the mitogen-activated protein (MAP) kinase signaling pathway. How signaling events downstream from BRAF affect the underlying program of gene expression is poorly understood. We show that the Brn-2 POU domain transcription factor is highly expressed in melanoma cell lines but not in melanocytes or melanoblasts and that overexpression of Brn-2 in melanocytes results in increased proliferation. Expression of Brn-2 is strongly upregulated by Ras and MAP kinase signaling. Importantly, the Brn-2 promoter is stimulated by kinase-activating BRAF mutants and endogenous Brn-2 expression is inhibited by RNA interference-mediated downregulation of BRAF. Moreover, silent interfering RNA-mediated depletion of Brn-2 in melanoma cells expressing activated BRAF leads to decreased proliferation. The results suggest that the high levels of Brn-2 expression observed in melanomas link BRAF signaling to increased proliferation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15024080      PMCID: PMC371133          DOI: 10.1128/MCB.24.7.2923-2931.2004

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  43 in total

1.  c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi.

Authors:  M Wu; T J Hemesath; C M Takemoto; M A Horstmann; A G Wells; E R Price; D Z Fisher; D E Fisher
Journal:  Genes Dev       Date:  2000-02-01       Impact factor: 11.361

Review 2.  Mitf from neural crest to melanoma: signal transduction and transcription in the melanocyte lineage.

Authors:  C R Goding
Journal:  Genes Dev       Date:  2000-07-15       Impact factor: 11.361

3.  Epidermal growth factor induction of apolipoprotein A-I is mediated by the Ras-MAP kinase cascade and Sp1.

Authors:  X L Zheng; S Matsubara; C Diao; M D Hollenberg; N C Wong
Journal:  J Biol Chem       Date:  2001-01-18       Impact factor: 5.157

4.  The gene encoding the T-box factor Tbx2 is a target for the microphthalmia-associated transcription factor in melanocytes.

Authors:  S Carreira; B Liu; C R Goding
Journal:  J Biol Chem       Date:  2000-07-21       Impact factor: 5.157

5.  Sp family members and nuclear factor-Y cooperatively stimulate transcription from the rat pyruvate kinase M gene distal promoter region via their direct interactions.

Authors:  K Yamada; T Tanaka; K Miyamoto; T Noguchi
Journal:  J Biol Chem       Date:  2000-06-16       Impact factor: 5.157

6.  Multiple binding sites in the growth factor receptor Xmrk mediate binding to p59fyn, GRB2 and Shc.

Authors:  C Wellbrock; M Schartl
Journal:  Eur J Biochem       Date:  1999-02

7.  Regulation of microphthalmia-associated transcription factor MITF protein levels by association with the ubiquitin-conjugating enzyme hUBC9.

Authors:  W Xu; L Gong; M M Haddad; O Bischof; J Campisi; E T Yeh; E E Medrano
Journal:  Exp Cell Res       Date:  2000-03-15       Impact factor: 3.905

8.  NF-Y and Sp1 cooperate for the transcriptional activation and cAMP response of human tissue inhibitor of metalloproteinases-2.

Authors:  Z D Zhong; K Hammani; W S Bae; Y A DeClerck
Journal:  J Biol Chem       Date:  2000-06-16       Impact factor: 5.157

9.  High frequency of BRAF mutations in nevi.

Authors:  Pamela M Pollock; Ursula L Harper; Katherine S Hansen; Laura M Yudt; Mitchell Stark; Christiane M Robbins; Tracy Y Moses; Galen Hostetter; Urs Wagner; John Kakareka; Ghadi Salem; Tom Pohida; Peter Heenan; Paul Duray; Olli Kallioniemi; Nicholas K Hayward; Jeffrey M Trent; Paul S Meltzer
Journal:  Nat Genet       Date:  2002-11-25       Impact factor: 38.330

10.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

View more
  40 in total

1.  FOXD3 is a mutant B-RAF-regulated inhibitor of G(1)-S progression in melanoma cells.

Authors:  Ethan V Abel; Andrew E Aplin
Journal:  Cancer Res       Date:  2010-03-23       Impact factor: 12.701

2.  Cortical migration defects in mice expressing A-RAF from the B-RAF locus.

Authors:  Guadalupe Camarero; Oleg Yu Tyrsin; Chaomei Xiang; Verena Pfeiffer; Sandra Pleiser; Stefan Wiese; Rudolf Götz; Ulf R Rapp
Journal:  Mol Cell Biol       Date:  2006-10       Impact factor: 4.272

3.  Modulation of Brahma expression by the mitogen-activated protein kinase/extracellular signal regulated kinase pathway is associated with changes in melanoma proliferation.

Authors:  Aanchal Mehrotra; Srinivas Vinod Saladi; Archit R Trivedi; Shweta Aras; Huiling Qi; Ashika Jayanthy; Vijayasaradhi Setaluri; Ivana L de la Serna
Journal:  Arch Biochem Biophys       Date:  2014-07-12       Impact factor: 4.013

4.  Cooperative antiproliferative signaling by aspirin and indole-3-carbinol targets microphthalmia-associated transcription factor gene expression and promoter activity in human melanoma cells.

Authors:  Kevin M Poindexter; Susanne Matthew; Ida Aronchik; Gary L Firestone
Journal:  Cell Biol Toxicol       Date:  2016-04-07       Impact factor: 6.691

Review 5.  Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy.

Authors:  Takami Sato; Mizue Terai; Yutaka Tamura; Vitali Alexeev; Michael J Mastrangelo; Senthamil R Selvan
Journal:  Immunol Res       Date:  2011-12       Impact factor: 2.829

6.  Phosphorylation of BRN2 modulates its interaction with the Pax3 promoter to control melanocyte migration and proliferation.

Authors:  Irina Berlin; Laurence Denat; Anne-Lise Steunou; Isabel Puig; Delphine Champeval; Sophie Colombo; Karen Roberts; Elise Bonvin; Yveline Bourgeois; Irwin Davidson; Véronique Delmas; Laurence Nieto; Colin R Goding; Lionel Larue
Journal:  Mol Cell Biol       Date:  2012-01-30       Impact factor: 4.272

Review 7.  Transcriptional deregulation underlying the pathogenesis of small cell lung cancer.

Authors:  Dong-Wook Kim; Keun-Cheol Kim; Kee-Beom Kim; Colin T Dunn; Kwon-Sik Park
Journal:  Transl Lung Cancer Res       Date:  2018-02

8.  In silico studies of the interaction between BRN2 protein and MORE DNA.

Authors:  Ivan Evangelista do Vale Coelho; Denise Costa Arruda; Alex Gutterres Taranto
Journal:  J Mol Model       Date:  2016-08-27       Impact factor: 1.810

Review 9.  Pigmentation PAX-ways: the role of Pax3 in melanogenesis, melanocyte stem cell maintenance, and disease.

Authors:  Jennifer D Kubic; Kacey P Young; Rebecca S Plummer; Anton E Ludvik; Deborah Lang
Journal:  Pigment Cell Melanoma Res       Date:  2008-12       Impact factor: 4.693

10.  Brn2 is a transcription factor regulating keratinocyte differentiation with a possible role in the pathogenesis of lichen planus.

Authors:  Ge Shi; Kyung-Cheol Sohn; Dae-Kyoung Choi; Yu-Jin Kim; Seong-Jin Kim; Bai-Sheng Ou; Yong-Jun Piao; Young Ho Lee; Tae-Jin Yoon; Young Lee; Young-Joon Seo; Chang Deok Kim; Jeung-Hoon Lee
Journal:  PLoS One       Date:  2010-10-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.